Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
about
The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 geneOld medications and new targeted therapies in systemic sclerosis.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.Antiviral Screening of Multiple Compounds against Ebola VirusSustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.
P2860
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of diffuse systemic ...... lind placebo-controlled trial.
@en
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum
@nl
type
label
Treatment of diffuse systemic ...... lind placebo-controlled trial.
@en
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum
@nl
prefLabel
Treatment of diffuse systemic ...... lind placebo-controlled trial.
@en
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum
@nl
P2093
P2860
P1476
Treatment of diffuse systemic ...... lind placebo-controlled trial.
@en
P2093
P2860
P356
10.1136/ANNRHEUMDIS-2013-203674
P407
P577
2013-09-25T00:00:00Z